Literature DB >> 18547546

GABAA receptor agonist mitigates homocysteine-induced cerebrovascular remodeling in knockout mice.

Munish Kumar1, Neetu Tyagi, Karni S Moshal, Utpal Sen, S B Pushpakumar, Thomas Vacek, David Lominadze, Suresh C Tyagi.   

Abstract

Individuals with homozygous deficiency in cystathionine-beta-synthase (CBS) develop high levels of homocysteine in plasma, a condition known as homocysteinuria. Mental retardation ensues with death in teens; the heterozygous live normally but develop vascular dementia and Alzheimer's disease (AD) in later part of life. The treatment with muscimol, a gamma amino butyric acid receptor-A (GABA(A)) agonist, mitigates the AD syndrome and vascular dementia. We tested the hypothesis that homocysteine (Hcy) antagonizes the GABA(A) receptor and behaves as an excitotoxic neurotransmitter that causes blood brain barrier (BBB) permeability and vascular dementia. The BBB permeability was measured by infusing Evan's blue dye (2% in saline 5 ml/kg concentration) in CBS-/+, GABA(A)-/-, CBS-/+/GABA(A)-/- double knockout, CBS-/+ mice treated with muscimol and wild type (WT) mice. Matrix Metalloproteinase (MMP-2, MMP-9), Tissue Inhibitor of Matrix Metalloproteinase (TIMP-3, TIMP-4), collagen-III and elastin levels were measured in whole brain by Western blot. These results suggested an increase in Evan's blue permeability: CBS-/+<GABA(A)-/-<CBS-/+/GABA(A)-/- compared to WT mice. Interestingly, in CBS-/+ mice treated with muscimol, BBB permeability was significantly decreased compared with the CBS-/+ group. There was a decrease in the TIMP-4 protein expression level, whereas the TIMP-3 level increased in CBS-/+, GABA(A)-/-, and CBS-/+/GABA(A)-/- mice compared to the WT. MMP-2 and MMP-9 expression significantly increased in all the groups compared to the wild type. The results suggested that Hcy caused cerebral interstitial remodeling in brain by distorting the extracellular matrix, thus increasing the blood brain permeability; treatment with muscimol mitigated BBB permeability.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18547546      PMCID: PMC2811264          DOI: 10.1016/j.brainres.2008.04.021

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  36 in total

1.  Tissue inhibitor of metalloproteinase-3 induces a Fas-associated death domain-dependent type II apoptotic pathway.

Authors:  Mark Bond; Gillian Murphy; Martin R Bennett; Andrew C Newby; Andrew H Baker
Journal:  J Biol Chem       Date:  2002-02-04       Impact factor: 5.157

2.  Abnormal expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in brain arteriovenous malformations.

Authors:  Tomoki Hashimoto; Gen Wen; Michael T Lawton; Nancy J Boudreau; Andrew W Bollen; Guo-Yuan Yang; Nicholas M Barbaro; Randall T Higashida; Christopher F Dowd; Van V Halbach; William L Young
Journal:  Stroke       Date:  2003-03-20       Impact factor: 7.914

Review 3.  Homocysteine and vascular dysfunction.

Authors:  S R Lentz
Journal:  Life Sci       Date:  1997       Impact factor: 5.037

4.  Vitamins B6, B12, and folate: association with plasma total homocysteine and risk of coronary atherosclerosis.

Authors:  P W Siri; P Verhoef; F J Kok
Journal:  J Am Coll Nutr       Date:  1998-10       Impact factor: 3.169

5.  Prevalence of hyperhomocyst(e)inemia in patients with peripheral arterial occlusive disease.

Authors:  M R Malinow; S S Kang; L M Taylor; P W Wong; B Coull; T Inahara; D Mukerjee; G Sexton; B Upson
Journal:  Circulation       Date:  1989-06       Impact factor: 29.690

6.  Myocardial matrix metalloproteinase(s): localization and activation.

Authors:  S C Tyagi; A Ratajska; K T Weber
Journal:  Mol Cell Biochem       Date:  1993-09-08       Impact factor: 3.396

Review 7.  Homocysteine and cardiovascular disease.

Authors:  H Refsum; P M Ueland; O Nygård; S E Vollset
Journal:  Annu Rev Med       Date:  1998       Impact factor: 13.739

8.  Differential inhibition of membrane type 3 (MT3)-matrix metalloproteinase (MMP) and MT1-MMP by tissue inhibitor of metalloproteinase (TIMP)-2 and TIMP-3 rgulates pro-MMP-2 activation.

Authors:  Huiren Zhao; M Margarida Bernardo; Pamela Osenkowski; Anjum Sohail; Duanqing Pei; Hideaki Nagase; Masahide Kashiwagi; Paul D Soloway; Yves A DeClerck; Rafael Fridman
Journal:  J Biol Chem       Date:  2003-12-16       Impact factor: 5.157

9.  A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase.

Authors:  P Frosst; H J Blom; R Milos; P Goyette; C A Sheppard; R G Matthews; G J Boers; M den Heijer; L A Kluijtmans; L P van den Heuvel
Journal:  Nat Genet       Date:  1995-05       Impact factor: 38.330

10.  Synergistic inhibition of [3H]muscimol binding to calf-brain synaptic membranes in the presence of L-homocysteine and pyridoxal 5'-phosphate. A possible mechanism for homocysteine-induced seizures.

Authors:  R Griffiths; D C Williams; C O'Neill; I C Dewhurst; C E Ekuwem; C D Sinclair
Journal:  Eur J Biochem       Date:  1983-12-15
View more
  15 in total

Review 1.  Vascular complications of cystathionine β-synthase deficiency: future directions for homocysteine-to-hydrogen sulfide research.

Authors:  Richard S Beard; Shawn E Bearden
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-10-22       Impact factor: 4.733

Review 2.  Is hyperhomocysteinemia an Alzheimer's disease (AD) risk factor, an AD marker, or neither?

Authors:  Jia-Min Zhuo; Hong Wang; Domenico Praticò
Journal:  Trends Pharmacol Sci       Date:  2011-06-20       Impact factor: 14.819

3.  Curcumin-primed exosomes mitigate endothelial cell dysfunction during hyperhomocysteinemia.

Authors:  A Kalani; P K Kamat; P Chaturvedi; S C Tyagi; N Tyagi
Journal:  Life Sci       Date:  2014-04-26       Impact factor: 5.037

4.  Folic acid mitigated cardiac dysfunction by normalizing the levels of tissue inhibitor of metalloproteinase and homocysteine-metabolizing enzymes postmyocardial infarction in mice.

Authors:  Natia Qipshidze; Neetu Tyagi; Utpal Sen; Srikanth Givvimani; Naira Metreveli; David Lominadze; Suresh C Tyagi
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-08-27       Impact factor: 4.733

5.  Matrix imbalance by inducing expression of metalloproteinase and oxidative stress in cochlea of hyperhomocysteinemic mice.

Authors:  Soumi Kundu; Neetu Tyagi; Utpal Sen; Suresh C Tyagi
Journal:  Mol Cell Biochem       Date:  2009-07-10       Impact factor: 3.396

6.  Role of microRNA29b in blood-brain barrier dysfunction during hyperhomocysteinemia: an epigenetic mechanism.

Authors:  Anuradha Kalani; Pradip K Kamat; Anastasia Familtseva; Pankaj Chaturvedi; Nino Muradashvili; Nithya Narayanan; Suresh C Tyagi; Neetu Tyagi
Journal:  J Cereb Blood Flow Metab       Date:  2014-05-07       Impact factor: 6.200

7.  Cobalamin deficiency, hyperhomocysteinemia, and dementia.

Authors:  Steven F Werder
Journal:  Neuropsychiatr Dis Treat       Date:  2010-05-06       Impact factor: 2.570

8.  Homocysteine decreases blood flow to the brain due to vascular resistance in carotid artery.

Authors:  Munish Kumar; Neetu Tyagi; Karni S Moshal; Utpal Sen; Soumi Kundu; Paras K Mishra; Srikanth Givvimani; Suresh C Tyagi
Journal:  Neurochem Int       Date:  2008-08-03       Impact factor: 3.921

9.  Apelin is required for non-neovascular remodeling in the retina.

Authors:  Jenny A G McKenzie; Marcus Fruttiger; Sabu Abraham; Clemens A K Lange; Jay Stone; Pranita Gandhi; Xiaomeng Wang; James Bainbridge; Stephen E Moss; John Greenwood
Journal:  Am J Pathol       Date:  2011-11-07       Impact factor: 4.307

10.  Hyperhomocysteinemia promotes vascular remodeling in vein graph in mice.

Authors:  Hongmei Tan; Chengwei Shi; Xiaohua Jiang; Muriel Lavelle; Caijia Yu; Xiaofeng Yang; Hong Wang
Journal:  Front Biosci (Landmark Ed)       Date:  2014-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.